Xortx announces research coverage initiated by a.g.p./alliance global partners

Calgary, alberta, dec. 09, 2021 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced today that james molloy, senior biotechnology analyst at a.g.p./alliance global partners, has initiated research coverage on xortx.
XRTX Ratings Summary
XRTX Quant Ranking